Currently available treatments for tuberculosis (TB) have serious limitations including lengthy duration of treatment, toxicity, and declining effectiveness as drug resistant TB strains become more prevalent. Therapies that target host processes involved in TB pathogenesis offer a new strategy for treating TB.
The START team reviewed recent scientific advances in host-directed TB therapeutics, summarizing findings in a landscape document. The landscape detailed nine biological pathways that are involved in the host response to TB infection and identified dozens of potential therapeutic compounds known to modulate these pathways. The landscape document was distributed to leading TB researchers and used as a springboard for discussion at an agenda-setting meeting organized by the TB Alliance and the Bill & Melinda Gates Foundation. Following the meeting, the START team worked with the project sponsor at the Foundation to transform the landscape document into a review article that has been submitted for publication.